Rapamycin Enhances Apoptosis and Increases Sensitivity to Cisplatin in Vitro

Cancer Research

Volumn 55, Issue 9, 1995, Pages 1982-1988

  Shi, Yufang ^a   Frankel, Andrea ^a   Mills, Gordon B ^a   Radvanyi, Laszlo G ^b   Miller, Richard G ^b   Penn, Linda Z ^c  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ASCOMYCIN; CISPLATIN; DNA FRAGMENT; PROTEIN KINASE; RAPAMYCIN; RECOMBINANT INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SIGNAL TRANSDUCTION;

ANIMAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CISPLATIN; DRUG SYNERGISM; FEMALE; HAMSTERS; HUMAN; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, PROMYELOCYTIC, ACUTE; LYMPHOCYTE ACTIVATION; MICE; OVARIAN NEOPLASMS; POLYENES; SENSITIVITY AND SPECIFICITY; SIROLIMUS; SUPPORT, NON-U.S. GOV'T; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0028925744     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Schreiber, S. L. Immunophilin-sensitive protein phosphatase action in cell signaling pathways. Cell, 70: 365–368, 1992.
2. McKeon, F. When worlds collide: immunosuppressants meet protein phosphatases. Cell, 66: 823–826, 1991.
3. Cyert, M. S. Immunosuppressants hit the target. Current Biol., 2: 18–20, 1992.
4. Kuo, C. J., Chung, J., Fiorentino, D. F., Flanagan, W. M., Blenis, J., and Crabtree, G. R. Rapamycin selectively inhibits interleukin-2 activated p70 S6 kinase. Nature (Lond.), 358: 70–73, 1992.
5. Sigal, N. H., and Dumont, F. J. Cyclosporin A, FK-506, and rapamycin: pharmacological probes of lymphocyte signal transduction. Annu. Rev. Immunol., 10: 519–560, 1992.
6. Chung, J., Kuo, C. J., Crabtree, G. R., and Blenis, J. Rapamycin-FKBP specifically blocks growth-dependent activation of and the signaling by the 70 kd S6 protein kinases. Cell, 69: 1227–1236, 1992.
7. Jefferies, H. B., Reinhard, C., Kozma, S. C., and Thomas, G. Rapamycin selectively represses translation of the polypyrimidine tract mRNA family. Proc. Natl. Acad. Sci. USA, 91: 4441–4445, 1994.
8. Price, D. J., Grove, J. R., Calvo, V., Avruch, J., and Bierer, B. E. Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science (Washington DC), 257: 973–977, 1992.
9. Jayaraman, T., and Marks, A. R. Rapamycin-FKBP12 blocks proliferation, induces differentiation, and inhibits cdc2 kinase activity in a myogenic cell line. J. Biol. Chem., 268: 25385–25388, 1993.
10. Shi, L., Nishioka, W. K., Th'ng, J., Bradbury, E. M., Litchfield, D. W., and Green-burg, A. H. Premature p34cd32 activation required for apoptosis. Science (Washington DC), 263: 1143–1145, 1994.
11. Wyllie, A. H., Kerr, J. F. R., and Currie, A. R. Cell death: the significance of apoptosis. Int. Rev. Cytol., 68: 251–305, 1980.
12. Shi, Y., Sahai, B. M., and Green, D. R. Cyclosporin A inhibits activation-induced cell death in T-cell hybridomas and thymocytes. Nature (Lond.), 339: 625–626, 1989.
13. Birer, B. E., Matilla, P. S., Standaert, R. F., Herzenburg, L. A., Burakoff, S. J., Crabtree, G., and Schreiber, S. L. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK-506 or rapamycin. Proc. Natl. Acad. Sci. USA, 87: 9231–9235, 1990.
14. Fotedar, A., Boyer, M., Smart, W., Widtman, J., Fraga, E., and Singh, B. Fine specificity of antigen recognition by a T cell hybridoma clone specific for poly 18: a synthetic polypeptide of defined sequence and conformation. J. Immunol., 135: 3028–3033, 1985.
15. Leo, O., Foo, M., Sachs, D. H., Samelson, L. E., and Bluestone, J. A. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc. Natl. Acad. Sci. USA, 84: 1374, 1987.
16. Penn, L. J. Z., Brooks, M. W., Laufer, E. M., Littlewood, T. D., Morgenstern, J. P., Evan, G. I., Lee, W. M. F., and Land, H. Domains of human c-myc protein required for autosuppression and cooperation with ras oncogenes are overlapping. Mol. Cell. Biol., 10: 4961–4966, 1990.
17. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65: 55–63, 1983.
18. Dumont, F. J., Staruch, M. J., Koprak, S. L., Melino, M. R., Sigal, N. H. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J. Immunol., 144: 251–258, 1990.
19. Duke, R. C., and Cohen, J. J. IL-2 addiction: withdrawal of growth factor activates a suicide program in dependent T cells. Lymph. Res., 5: 289–299, 1986.
20. Bissonnette, R. P., Echeverrie, F., Mahboubi, A., and Green, D. R. Apoptotic cell death-induced by c-myc is inhibited by bcl-2. Nature (Lond.), 359: 552–554, 1992.
21. Fanidi, A., Harrington, E. A., and Evan, G. I. Cooperative interaction between c-myc and bcl-2 protooncogenes. Nature (Lond.), 359: 554–556, 1992.
22. Shi, Y., Glynn, J. M., Guilbert, J. L., Cotter, T. G., Bissonnette, R. P., and Green, D. R. Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. Science (Washington DC), 257: 212–214, 1992.
23. Evans, G. I., Wyllie, A. H., Guilbert, C. S., Littlewood, T. D., Land, H., Brooks, M., Waters, C. M., Penn, L. Z., and Hancock, D. C. Induction of apoptosis in fibroblasts by c-myc protein. Cell, 69: 119–128, 1992.
24. Shi, Y., Bissonnette, R. P., Parfrey, N., Szalay, M. G., Kubo, R. T., and Green, D. R. In vivo administration of monoclonal antibodies to the CD3/T cell receptor complex induces cell death in immature thymocytes. J. Immunol., 146: 3340–3346, 1991.
25. Shi, Y., Szalay, M. G., Paskar, L., Boyer, M., Singh, B., and Green, D. R. Activation-induced cell death in T cell hybridoma is due to apoptosis: morphological aspects and DNA fragmentation. J. Immunol., 144: 3326–3333, 1990.
26. Wyllie, A. H. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature (Lond.), 284: 555–557, 1980.
27. Hickman, J. A. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev., 11: 121–139, 1992.
28. Kahan, B. D., Chang, J. Y., and Segal, S. N. Preclinical evaluation of a new potent immunosuppressive agent, rapamycin. Transplantation (Baltimore), 52: 185–191,1991.
29. Chu, G. Cellular response to cisplatin. J. Biol. Chem., 269: 787–790, 1994.
30. Ormerod, M. G., O'Neill, C. F., Robertson, D., and Harrap, K. R. Cisplatin induces apoptosis in a human ovarian carcinoma cell line without concomitant interaucleo-somal degradation of DNA. Exp. Cell Res., 211: 231–237, 1994.
31. Allen, P. D., Bustin, S. A., MaCey, M. G., Johnston, D. H., Williams, N. S., and Newland, A. C. Programmed cell death (apoptosis) in immunity and haematological neoplasia. Br. J. Biochem. Sci., 50: 135–149,1993.
32. White, E. Death-defying acts: a meeting review on apoptosis. Genes Dev., 7: 2277–2284, 1993.
33. Barry, M. A., Behnke, C. A., and Eastman, A. Activation of programmed cell death (apoptosis) by cisplatin, other anti-cancer drugs, toxins and hyperthermia. Biochem. Pharmacol., 40: 2353–2362, 1990.
34. Gateley, D. P., and Howell, S. B. Cellular accumulation of the anticancer agent cisplatin: a review. Br. J. Cancer, 67: 1171–1176, 1993.
35. Napoli, K. L., and Kahan, B. D. Sample clean-up and high-performance liquid chromatographic techniques for measurement of whole blood rapamycin concentrations. J. Chromatog. B., 654: 111–120, 1994.